课题基金 / 基金详情

Prognostic Biomarkers in Chronic Kidney Disease

Prognostic Biomarkers in Chronic Kidney Disease
慢性肾脏病的预后生物标志物
批准号:
9749995
负责人:
Farsad Afshinnia
金额:
$16.63万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-17 至 2020-11-30
关键词:
21 year oldAddressAgeAmino AcidsAreaBiological MarkersCardiovascular DiseasesCardiovascular systemChronic Kidney FailureChronic Kidney InsufficiencyCitric AcidCitric Acid CycleClassificationClinicalCohort StudiesComorbidityControl GroupsCreatinineDataData CollectionDetectionDiabetes MellitusDiagnosticDiscriminationDiseaseDisease ProgressionEnd stage renal failureEnzymesEuropeanExclusion CriteriaExcretory functionFastingFramingham Heart StudyGene ExpressionGenesGlomerular Filtration RateGoalsInjuryKidneyLaboratoriesLinkLipidsLogistic RegressionsMass Spectrum AnalysisMeasurementMeasuresMetabolicMetabolic DiseasesMetabolic MarkerMetabolic PathwayMethodsNucleotidesOutcomeParticipantPathway interactionsPatient CarePatient-Focused OutcomesPatientsPerformancePhasePhysical ExaminationPreventive InterventionProcessPrognostic MarkerProteinsPublic HealthRaceReceiver Operating CharacteristicsRegression AnalysisRegulationRenal TissueRenal functionReportingResourcesRiskSample SizeSamplingSerumSpecificityTestingTherapeutic InterventionTimeTissuesUnited StatesValidationacylcarnitinebasebiobankbioinformatics toolbiomarker identificationbiomarker panelcandidate markercardiovascular risk factorcare outcomesclinical careclinical phenotypecohortdemographicsdesigndiabetic patientdifferential expressionhigh riskhigh risk populationimprovedinclusion criteriaindexingkidney biopsymetabolomicsmortalitynovelnovel markeroutcome predictionpredictive modelingprognosticprognostic valuepublic health relevancesample collectionsexsolutestatisticsstudy populationtranscriptomicsurea cycleurinary

项目摘要

项目成果

Farsad Afshinnia的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):在慢性肾脏疾病(CKD)的临床病程中识别具有预后价值的新的机制标记物将提供对疾病过程的更好的了解,并通过在早期阶段识别高危人群来改善患者的护理。重要的是,机械途径的识别将服从于新的预防或治疗干预措施。本研究旨在通过比较ANCUAL(氨基酸、核苷酸、柠檬酸和尿素循环的中间产物、酰肉碱和脂类)代谢组合与传统标志物(血肌酐、尿蛋白、EGFR)在CKD早期的受试者工作特征(ROC)曲线下的面积,来比较ANCUAL对CKD进展的预测能力。我们还旨在探索所提出的代谢标记物与参与调节这些标记物的基因的肾组织表达水平之间的联系。方法:这将是一项嵌套病例队列研究。研究人群包括用于代谢物测量的慢性肾功能不全队列(CRIC)的参与者,以及用于转录组-代谢组学综合分析的临床表型资源和生物库核心(CPROBE)。入选标准是CRIC参与者的入门年龄为21至74岁,EGFR为30-70岁,CPROBE参与者的入门EGFR为30毫升/分钟或更高。排除标准与CRIC和CPROBE核心研究相同。抽样:来自CRIC参与者;病例组定义为100名进展为终末期肾病的患者,包括50名糖尿病患者和50名非糖尿病患者。对照组为年龄、性别、种族、糖尿病和基线EGFR相匹配的100例患者(N=200)。这一抽样将被重复,以从CRIC获得另外200名处于验证阶段的患者(总数=400)。从CPROBE参与者中选择42名从肾脏活检中获得可用基因表达数据的参与者。数据收集:从CRIC开始,从基线开始收集空腹血清样本。首先,在前200名CRIC参与者中,样本将接受靶向代谢组学分析(MS),以量化ANCUAL小组。随后将进行非靶向代谢分析,以扩大初始小组,随后对新确定的预后代谢物进行正交量化,以验证从非靶向平台发现新化合物。然后,扩展的ANCUAL小组将在目标平台上在另外200个来自中国保监会的独立样本中进行复制,以验证最终的小组。最后一步,将在CPROBE参与者的基线血清样本中对最终小组进行量化,以尝试与他们的转录组数据相结合。预测因素是根据MS得出的扩展ANCUAL小组结果是事件ESRD。协变量包括人口统计学、化验值、合并症、体检结果和样本收集时的人体测量学测量。分析:多元Logistic回归分析将用于在差异表达的基线小组中识别多小组标记的独立成分。C-统计量将用于比较多面板标记物的受试者工作特征(ROC)曲线下的面积与传统生物标记物区分 非进步者中的进步者。将采用综合区分改进、净重分类指数和C-统计量来评估扩大后的小组与基线小组相比的分类改进情况。使用Logistic回归对相关预后协变量进行调整,以评估建议小组的四分位数发生终末期肾病的风险。基因和代谢集浓缩分析将用于测试不同调节代谢途径的浓缩。生物信息学工具将用于路径识别。
英文摘要
DESCRIPTION (provided by applicant): Identification of novel mechanistic markers with prognostic value in clinical course of chronic kidney disease (CKD) will provide a better understanding of disease process and improve care of the patients by identification of high risk groups at earlier stages. Importantly, identification of mechanistic pathways will be amenable to novel preventive or therapeutic interventions. This study is aimed at comparing the predictive power of ANCUAL (Amino acids, Nucleotides, intermediates of Citric acid and Urea cycles, Acylcarnitines, and Lipids) metabolic panel to predict progression of CKD by comparing their area under Receiver Operating Characteristics (ROC) curves with those of the traditional markers (serum creatinine, urinary protein, eGFR) at early stage. We also aim to explore the link between the proposed metabolic markers with the renal tissue expression level of genes involved in regulation of these markers. Methods: This will be a nested case-cohort study. Study populations consist of participants of Chronic Renal Insufficiency Cohort (CRIC) for measurement of metabolites, and Clinical Phenotyping Resource and Biobank Core (CPROBE) for transcriptomics- metabolomics integrative analysis. Inclusion criteria are entry age of 21 to 74 years with eGFR of 30-70 for CRIC participants, and entry eGFR of 30 mL/min or higher for CPROBE participants. Exclusion criteria are the same as CRIC and CPROBE core studies. Sampling: From CRIC participants; case group is defined as 100 patients who have progressed to ESRD including 50 patients with diabetes and 50 patients without diabetes. Control group will be 100 patients matched by age, sex, race, diabetes, and baseline eGFR (N=200). This sampling will be replicated to get another 200 patients from CRIC in the validation phase (total=400). From CPROBE participants; 42 participants with available gene expression data obtained from kidney biopsy will be selected. Data collection: Starting with CRIC, fasting serum samples from baseline will be collected. First, samples will be subjected to targeted metabolomics analysis by mass spectrometry (MS) for quantification of ANCUAL panel, in the first 200 CRIC participants. This will be followed by an untargeted metabolomic analysis for expansion of the initial panel, followed by an orthogonal quantification of the newly identified prognostic metabolites to validate the discovery of the new compounds from untargeted platform. The expanded ANCUAL panel will then undergo replication in a targeted platform in another 200 independent samples from CIRC to validate the final panel. At last step the final panel will be quantified in the baseline serum samples of CPROBE participants in an attempt to integrate with their transcriptomics data. Predictors are the expanded ANCUAL panel derived from MS. Outcome is incident ESRD. Covariates include demographics, laboratory values, comorbidities, physical examination findings and anthropometric measures from the time of sample collection. Analysis: Multiple logistic regression analysis will be applied to identify the independent components of a multi panel marker among the differentially expressed baseline panel. C-statistics will be applied to compare the area under Receiver Operating Characteristics (ROC) curve of the multi-panel marker with that if the traditional biomarkers for discrimination of progressors from non-progressors. Integrated discrimination improvement, net reclassification index, and C-statistics will be applied to assess the classification improvement of the expanded panel compared to baseline panel. Risk of ESRD by quartiles of the proposed panel will be estimated using logistic regression adjusting for relevant prognostic covariates. Gene and metabolic set enrichment analysis will be applied to test enrichment of differentially regulated metabolic pathways. Bioinformatics tools will be used for pathway recognition.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/ctr.12964
发表时间: 2017-06-01
期刊: CLINICAL TRANSPLANTATION
影响因子: 2.1
作者: [Shamsaeefar, Alireza, Shafiee, Mohammad, Malekhosseini, Seyed Ali]
通讯作者: Malekhosseini, Seyed Ali
DOI: 10.1093/ckj/sfaa031
发表时间: 2021-04
期刊: Clinical kidney journal
影响因子: 4.6
作者: [Konje VC, Rajendiran TM, Bellovich K, Gadegbeku CA, Gipson DS, Afshinnia F, Mathew AV, Michigan Kidney Translational Core CPROBE Investigator Group]
通讯作者: Michigan Kidney Translational Core CPROBE Investigator Group
Lipidomic predictors of heart failure in chronic kidney disease
Role of Acetyl CoA carboxylase in type 2 diabetic kidney disease
Lipidomic Predictors of Diabetic Kidney Disease Progression in Patients with Type-1 Diabetes
Prognostic Biomarkers in Chronic Kidney Disease
海外基金